Apremilast in refractory orogenital ulcers and other manifestations of Behçet's disease. A national multicentre study of 51 cases in clinical practice.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Atienza-Mateo B
  • Martín-Varillas JL
  • Graña J
  • Espinosa G
  • Moriano C
  • Pérez-Sandoval T
  • García-Armario MD
  • Castellví I
  • Olivé A
  • Ybáñez A
  • Martinez-Ferrer A
  • Narváez J
  • Romero-Yuste S
  • Ojeda S
  • Ros I
  • Loricera J
  • Calvo-Río V
  • Castañeda S
  • Gonzalez-Gay MA
  • Blanco R
  • Spanish Collaborative Group of Refractory Behçet's Disease

Grupos

Abstract

The objective of the present study was to assess the efficacy of apremilast (APR) in the management of refractory oral and/or genital ulcers in patients with Behçet's disease (BD).

Datos de la publicación

ISSN/ISSNe:
0392-856X, 1593-098X

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY  CLINICAL & EXPER RHEUMATOLOGY

Tipo:
Article
Páginas:
69-75
DOI:
PubMed:
33331268
Factor de Impacto:
1,184 SCImago
Cuartil:
Q2 SCImago

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Campos de Estudio

Compartir